Atlas FDA

Synerg Everolimus Eluting Conronary Stent System

FDA premarket approval P150003/S033 · decided 2017-09-13

Approval details

PMA number
P150003
Supplement
S033
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
Synerg Everolimus Eluting Conronary Stent System
Generic name
Coronary drug-eluting stent
Applicant
Boston Scientific Corporation
Date received
2017-08-18
Decision date
2017-09-13
Days to decision
26 days
Decision code
OK30
Product code
NIQ
Advisory committee
Cardiovascular
Expedited review
No
Location
Maple Grove, MN
Statement
Removal of a redundant inspection step.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
TheraSphere 360™ Y-90 Management Platform (K262462)Boston Scientific Corporation2026-07-24
FARADRIVE™ Steerable Sheath (M004PF21M402) (K262165)Boston Scientific Corporation2026-07-24
OBSIDIO Conformable Embolic (K261488)Boston Scientific Corporation2026-07-24
WallFlex Esophageal Stent System;Agile Esophageal Over-the-Wire (OTW) Stent System (K261978)Boston Scientific Corporation2026-07-10
RIVOS™ EUS Access Device (M00553900) (K260428)Boston Scientific Corporation2026-06-17
MOSES Raydar™ (K260100)Boston Scientific Corporation2026-05-18
TruSelect™ 2.6 Microcatheter (K260771)Boston Scientific Corporation2026-05-15
Asurys Fluid Management System (K251273)Boston Scientific Corporation2026-03-27